Rchr
J-GLOBAL ID：201701017821046204   Update date: Dec. 24, 2025

Fujino Toshio

フジノ トシオ | Fujino Toshio
Affiliation and department：
Massachusetts General Hospital Cancer Center

About Massachusetts General Hospital Cancer Center


Job title： Postdoctoral Research Fellow
Research field  (1)： Tumor diagnostics and therapeutics
Research keywords  (7)： Lineage plasticity ,  DTPCs ,  Lung cancer ,  Targeted therapy ,  MET ,  ALK ,  EGFR
Research theme for competitive and other funds  (4)：
  • 2022 - 2026 Elucidation and Overcoming the Primary Resistance Mechanism in MET-driven Lung Cancer
  • 2021 - 2023 Analysis of CBL gene mutations as a novel therapeutic target for lung cancer
  • 2019 - 2021 Development of new treatment strategy for lung cancer haboring MET exon14 mutation
  • 2016 - 2019 Molecular targeted therapy against adenocarcinoma of the lung harboring MET exon 14 skipping mutation
Papers (137)：
  • Jaime L Schneider, Kiran Kurmi, Yutong Dai, Ishita Dhiman, Shakchhi Joshi, Brandon M Gassaway, Christian W Johnson, Nicole Jones, Zongyu Li, Christian P Joschko, et al. GUK1 activation is a metabolic liability in lung cancer. Cell. 2025
  • Jessica J. Lin, Joshua C. Horan, Anupong Tangpeerachaikul, Aurélie Swalduz, Augusto Valdivia, Melissa L. Johnson, Benjamin Besse, D. Ross Camidge, Toshio Fujino, Satoshi Yoda, et al. NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations. Cancer Discovery. 2024
  • Akira Hamada, Kenichi Suda, Masaya Nishino, Keiko Obata, Hana Oiki, Tomoyo Fukami, Shota Fukuda, Toshio Fujino, Shuta Ohara, Takamasa Koga, et al. Secondary mutations of the EGFR gene that confer resistance to mobocertinib in EGFR exon 20 insertion. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2023
  • Takamasa Koga, Junichi Soh, Akira Hamada, Yuki Miyano, Toshio Fujino, Keiko Obata, Shuta Ohara, Masaya Nishino, Masato Chiba, Masaki Shimoji, et al. Clinical Relevance of Patient-Derived Organoid of Surgically Resected Lung Cancer as an In Vitro Model for Biomarker and Drug Testing. JTO clinical and research reports. 2023. 4. 9. 100554-100554
  • Sun Min Lim, Toshio Fujino, Chulwon Kim, Gwanghee Lee, Yong-Hee Lee, Dong-Wan Kim, Jin Seok Ahn, Tetsuya Mitsudomi, Taiguang Jin, Sang-Yoon Lee. BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2023. 29. 16. 3004-3016
ｍore...
MISC (62)：
ｍore...
Patents (1)：
  • Drugs for lung cancer that has acquired resistance to type I TKIs.
Books (4)：
  • Respiratory Medicine
    2022
  • Respiratory Journal
    2020
  • PROGRESS IN MEDCINE
    lifescience 2018 ISBN:9784898016374
  • 検診胸部X線写真の読影
    国際医学出版 2016 ISBN:4861022630
Lectures and oral presentations  (11)：
  • Elucidating mechanisms of cancer cell persistence to lorlatinib in ALK positive NSCLC
    (Annual Lung Cancer SPORE Meeting 2025)
  • Elucidating mechanisms of cancer cell persistence to lorlatinib in ALK positive NSCLC
    (the American Association for Cancer Research Annual Meeting 2025 2025)
  • Towards Overcoming On-target Resistance to MET-TKIs: Insights from Preclinical Model
    (MET in Cancer, Lille city in France 2023)
  • Preclinical Activity of NVL-655 in Patient-Derived Models of ALK Cancers, Including Those with Lorlatinib-Resistant G1202R/L1196M Compound Mutation
    (EORTC-NCI-AACR 2022 2022)
  • Proposal of foretinib as second-line TKI after capmatinib/tepotinib treatment failure in NSCLC with MET exon14 mutation.
    (IASLC 2022 World Conference on Lung Cancer 2022)
ｍore...
Education (2)：
  • 2017 - 2020 Kindai University Faculty of Medicine Graduate School of Medical Sciences
  • 2006 - 2012 Nagoya City University
Work history (5)：
  • 2022/04 - 現在 Massachusetts General Hospital Cancer Center Research fellow
  • 2017/04 - 2022/03 Kindai University Faculty of Medicine Thoracic Surgery
  • 2017/01 - 2017/03 Nagoya City University Thoracic Surgery
  • 2014/04 - 2016/12 Seirei Mikatahara General Hospital Thoracic Surgery
  • 2012/04 - 2014/03 Ijinkai Takeda General Hospital
Committee career (1)：
  • 2024/12 - 現在 Break Through Cancer PoweRD 2 Cure ALK+ Lung Cancer TeamLab
Awards (9)：
  • 2025/06 - Lung Cancer SPORE Annual Lung Cancer SPORE Meeting Travel Award
  • 2022/04 - Takeda Science Foundation Research grant for Study Abroad
  • 2022/04 - 日本呼吸機学会 リリー・オンコロジー・フェローシップ・プログラム
  • 2021/07 - 近畿大学 医学会賞
  • 2020/11 - The Japan Lung Cancer Society Young Scientist Award
Show all
Association Membership(s) (11)：
AACR ,  The Japanese Respiratory Society ,  IASLC ,  ASCO ,  THE JAPAN SOCIETY FOR RESPIRATORY ENDOSCOPY ,  THE JAPAN LUNG CANCER SOCIETY ,  THE JAPANESE ASSOCIATION FOR THORACIC SURGERY ,  The Japanese Association for Chest Surgery ,  JAPAN SURGICAL SOCIETY ,  THE JAPANESE CANCER ASSOCIATION ,  THE JAPANESE ASSOCIATION FOR MOLECULAR TARGET THERAPY OF CANCER
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page

TOP

BOTTOM